| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| Other Sizes |
| Targets |
No direct biological target; the thiol group reacts with maleimide-functionalized biomolecules for conjugation; the DSPE moiety anchors into lipid bilayers for nanoparticle formulation.
|
|---|---|
| ln Vitro |
DSPE-PEG-SH (MW 2000) has no direct biological activity; it is a formulation excipient. The amphiphilic polymer forms lipid bilayers in aqueous solution, enabling encapsulation of active molecules (e.g., mRNA, siRNA, small molecule drugs) for drug delivery systems such as mRNA vaccines.
|
| ln Vivo |
No in vivo activity data for the PEG-lipid itself; DSPE-PEG-SH formulations are used in vivo as drug delivery vehicles (e.g., lipid nanoparticles, liposomes) that encapsulate therapeutic payloads, improving circulation time and targeted delivery.
|
| Enzyme Assay |
Not applicable; chemical conjugation efficiency is assessed by reacting the thiol group with maleimide-functionalized molecules (e.g., antibodies, peptides). The reaction is monitored by Ellman's assay (colorimetric detection of free thiols) or by HPLC.
|
| Cell Assay |
Liposomes or lipid nanoparticles (LNPs) prepared with DSPE-PEG-SH are mixed with maleimide-functionalized targeting ligands (e.g., antibodies) to form targeted formulations. Cellular uptake is assessed by incubating targeted nanoparticles with cells and measuring payload delivery by flow cytometry or confocal microscopy.
|
| Animal Protocol |
Mice bearing tumor xenografts receive DSPE-PEG-SH-formulated nanoparticles encapsulating therapeutic payloads (e.g., mRNA, siRNA, doxorubicin) via intravenous injection (0.5-5 mg lipid/kg). Biodistribution is assessed by imaging of fluorescently labeled nanoparticles or by measuring payload concentrations in tissues by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Not applicable; DSPE-PEG-SH is a formulation component, not a therapeutic agent. In the context of lipid nanoparticles, the PEG component extends circulation half-life and reduces opsonization, improving pharmacokinetic properties of the encapsulated payload.
|
| Toxicity/Toxicokinetics |
No toxicity data for DSPE-PEG-SH alone; PEGylated phospholipids have low inherent toxicity and are generally recognized as safe (GRAS) for use in pharmaceutical formulations. The thiol group can react with endogenous proteins, but at formulation concentrations this is minimal.
|
| References |
[1]. Gao Y, Sun Y, Liao G, Zhang H, Long Q. DSPE-PEG polymers for improving pulmonary absorption of poorly absorbed macromolecules in rats and relative mechanism. Drug Dev Ind Pharm. 2021;47(2):337-346.
|
| Additional Infomation |
DSPE-PEG-SH (MW 2000) is a research-grade formulation excipient for liposome and lipid nanoparticle preparation. It is not a drug and has no clinical trial or marketing approval status. For research use only in drug delivery, gene therapy, and vaccine development.
|
| Molecular Weight |
2000(Average)
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~6.67 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
